78 to 0.96 years when the monthly probability of chronic AIDS mortality was increased or decreased by 50%. Use of mean chronic AIDS mortality risks for CD4 counts of >200 cells/μL, rather than the upper bound of the 95% CI used in the base case analysis, decreased the incremental gain in life

expectancy attributable to first-line efavirenz use to 0.51 years. Mean projected life expectancy for women receiving an efavirenz-based first-line ART regimen starting at CD4<500 cells/μL was 30.45 life years, while mean life expectancy for women who delayed efavirenz use and were treated with an alternative initial ART regimen which did not contain efavirenz was 29.53 life years. The life expectancy gain attributable Venetoclax to using an efavirenz-based initial antiretroviral regimen was 0.92 years. Increasing the discount rate from 0% (base case) to 5%

lowered incremental life expectancy gains attributable to use of an efavirenz-based first-line ART regimen from 0.89 to 0.21 years, a difference of 0.68 years. For women without efavirenz exposure during pregnancy, the rate of teratogenic events was 72.46 events per 100 000 women (Table 4). For women exposed to efavirenz during pregnancy, the rate was 77.26 events per 100 000 women. We conducted a sensitivity analysis using age-group-specific pregnancy rates for women aged 15–24, 25–34 and 35–44 years. Using a pregnancy rate of 18.1 pregnancies per 100 person-years for women aged 15–24 years, the number of teratogenic events with use of efavirenz Sunitinib cost was 188.96 events per 100 000 women (11.73 excess events per 100 000 women). In contrast, using a pregnancy rate of 1.4 pregnancies per 100 person-years for women aged 35–44 years, the risk of excess teratogenic events decreased to 0.91 events per 100 000 women. Results of other one-way sensitivity analyses on the rate components of the decision model are summarized in Table 4. When the live birth rate was

varied from 27% to 45% (base case rate: 36%), the excess risk of teratogenic events attributable to efavirenz use ranged from 3.60 to 5.99 events per 100 000 women. When the rate of teratogenic events with efavirenz was varied from 1.60% to 4.90%, the excess teratogenicity risk ranged from −29.84 to 58.08 events per 100 000 women. Here, a negative risk of excess teratogenic events suggests that efavirenz use confers no excess teratogenicity Baricitinib risk beyond the background risk. Figure 1 shows the results of a two-way sensitivity analysis on the prevalence of teratogenic events with efavirenz use and the pregnancy rate. For women aged 15–24 years with the highest pregnancy rate (18.1 pregnancies per 100 person-years) and the highest teratogenicity risk (4.9%; the upper bound of the 95% CI for the mean rate of teratogenicity with efavirenz), the estimated number of excess teratogenic events was 142.05 events per 100 000 women. For women aged 35–44 years with the lowest pregnancy rate (1.